The cancer microenvironment plays a central role in cancer development, growth, and homeostasis. This paradigm suggests that cancer fibroblasts support cancers, probably in response to stimuli received from the cancer cells. We aimed at investigating whether extracellular vesicles (EVs) can shuttle microRNA (miR) species between cancer-associated fibroblasts (CAFs) and cancer cells. To this end, we extracted EVs according to published protocols. EVs were studied for their miR content by quantitative reverse-transcription polymerase chain reaction. EVs were transfected with select miR species and utilized in vitro as well as in vivo in a rat model of cholangiocarcinoma (CCA). We found that miR-195 is downregulated in CCA cells, as well as in adjoining fibroblasts. Furthermore, we report that EVs shuttle miR-195 from fibroblasts to cancer cells. Last, we show that fibroblast-derived EVs, loaded with miR-195, can be administered in a rat model of CCA, concentrate within the tumor, decrease the size of cancers, and improve survival of treated rats. Conclusion: EVs play a salient role in trafficking miR species between cancer cells and CAFs in human CCA. Understanding of these mechanisms may allow devising of novel therapeutics. (HEPATOLOGY 2017;65:501-514).
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C holangiocarcinoma (CCA), pancreatic carcinoma, and other cancers display a strong desmoplastic reaction that produces intimate contact between cancer cells and tissue fibroblasts. This strong desmoplastic reaction has long been assumed to exert antineoplastic effects, but recent studies support a new paradigm whereby cancer-associated fibroblasts (CAFs) intimately participate in cancer growth and metastasis. (1) (2) (3) (4) (5) (6) (7) (8) This hypothesis is supported by an array of observations, including (1) the cancer-potentiating nature of fibrotic liver, (9) (2) reports of stromal cells promoting cancer cell growth, migration, and invasiveness, (10) and (3) the fact that stroma-derived factors (e.g., platelet-derived growth factor, periostin, tenascin-C, thrombospondin-I, and galectin-1) can also promote the neoplastic properties of cancer cells. (11) (12) (13) (14) Extracellular vesicles (EVs) are derived from the plasma membrane or multivesicular bodies. (15) EVs can carry RNA species, including messenger RNA (mRNA) and microRNA (miR), as well as proteins, lipids, and transposable elements or amplified gene sequences. (15, 16) EVs are released into the pericellular environment, as well as into the circulating blood or other body fluids, and can transmit signals from one cell to another. (17) In addition, some of the transferred molecules appear to function in the cytoplasm of recipient cells, suggesting the existence of an intercellular vesicle trafficking pathway.
In the current study, we sought to identify miRs that are selectively suppressed in stromal cells in the presence of cocultured CCA cells. Three candidate miRs were identified, including miR-195. We report here that overexpression of miR-195 in hepatic stellate cells (HSCs) or portal fibroblasts inhibits the growth, migration, and metastasis of cocultured CCA cells, and that this effect is mediated, at least in part, by miR-195-containing, stroma-derived EVs. Furthermore, we observed that systemic injection of miR-195-loaded, stroma-derived EVs inhibited CCA tumor growth and prolonged survival in a rat model of CCA. These and other results indicate that EVs derived from stromal cells can be used to deliver therapeutic molecules to CCA cells in vitro and in vivo, thereby inhibiting cancer cell growth and extending the life span of tumor-bearing animals.
Materials and Methods

CELL CULTURE
LX2 is a human liver stellate cell line derived to study fibrogenesis. (18) HuCCT1 was derived from a patient with a moderately differentiated adenocarcinoma of the intrahepatic biliary tree. (19) SG231 is a CCA cell line derived as described. (20) TFK1 is an extrahepatic CCA cell line. (21) BDEneu and BDEsp are rat intrahepatic CCA cell lines derived as described. (22) RGF is a rat portal fibroblast cell line established by Fausther et al. (23, 24) H69, a gift from Dr. Jefferson (Tufts University, Boston, MA), are normal human intrahepatic cholangiocytes derived from a normal liver preceding liver transplantation. (25) All cell lines were maintained and grown as described. (18) (19) (20) (21) (22) 
EV PREPARATION AND CHARACTERIZATION
EVs were separated by ultracentrifugation, as described, (26) from LX2 cell-culture medium that had been cultured for 72 hours with EV-free fetal bovine serum (FBS). Multiparameter nanoparticle optical analysis (Nanosight) and a transmission electron microscope (TEM) were utilized to determine the shape, size, and tracking the brownian movement of EVs. Western blotting for EV-specific proteins was performed with anti-CD63 antibody (Santa Cruz, Dallas, Texas) and anti-TSG-101 antibody (Abcam, Cambridge, MA) as described. (26) 
QUANTITATIVE REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION FOR miR EXPRESSION
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed to detect the miR-195 expression in EVs, CCA cell lines, and CCA tumor mass cells. For miR-195 expression in EVs, we used cel-miR-39 as a control, whereas for miR-195 expression in cells, RNU6B was used to normalize the data as described. (26) 
PLASMIDS, TRANSFECTION, AND LENTIVIRUS/RETROVIRUS INFECTION
Vectors were purchased from Addgene (Cambridge, MA). Viral supernatants were produced by transfection of HEK-293T cells with a packaging plasmid (pVSV-G). BDEneu cells were infected with viral supernatant
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with Polybrene at a final concentration of 8 lg/uL. pCDH1-EF1-mCherry-TSG101-IRES-GFP (green fluorescent protein) was used to infecft LX2 cells. GFP-positive cells were sorted and used to isolate EVs with mCherry on the surface. pMSCV-loxp-dsRedloxp-eGFP-Puro-WPRE was used as above to produce viral particles that were then used to infect BDEneu cells. Puromycin was used to select for stably infected cells. When a Cre-recombinase encoding plasmid is detected, cells switch color from red fluorescent protein (RFP) to GFP after excision of the loxpdsRed-loxP element.
CONDITIONED MEDIA PREPARATION
Confluent LX2-miR-195 mimic/NSM cells were incubated with Delbecco's modified Eagle's medium supplemented with penicillin/streptomycin and 0% FBS. Three days later, the conditioned media were collected, filtered, and used immediately.
ANIMAL STUDIES
Fischer 344 male (150-170 g) were purchased from Harlan (Frederick, MD) and housed in the animal facility at Johns Hopkins University (Baltimore, MD). All animal work was approved by and conducted in accord with the guidelines of the Institutional Animal Care and Use Committee at Johns Hopkins University. For the CCA rat model, Fischer 344 male rats were anesthetized and then inoculated with 1 3 10 6 BDEneu cells in 100 lL of Hank's balanced salt solution injected into the left liver lobe, followed by ligation of the common bile duct. Rats were monitored daily until day 5 or day 15, when the treatment with miR-loaded EVs started.
TREATMENT OF CCA RATS WITH miR-195-LOADED EVs
Initially, 6 CCA rats were randomized into two groups. Starting at day 5, rats received EV loaded with miR-195 mimic/NSM by tail veil injections every 2 days. After 25 days, rats were sacrificed, tumor weight and size were measured, and tissue specimen frozen in optimal cutting temperature (OCT) compound. Tissue sections were stained with primary antibodies and detected using Alexa Fluor dye-conjugated secondary antibodies. Microphotographs were obtained using a Zeiss laser scanning microscope (LSM 510; Oberkochen, Germany). In addition, single-cell suspension from tumor masses was used to sort the BDEneu cells with RFP fluorescence. miR-195 levels in miR-195-treated rats and NSMtreated controls were measured by RT-PCR.
KAPLAN-MEYER SURVIVAL CURVES
In a follow-up animal in vivo experiment, 20 CCA rats were randomized in a control group of 9 CCA rats treated with NSM and a treatment group of 11 rats, treated with miR-195 mimic, both starting from day 15. Animals were monitored daily, and the date of death of each rat was recorded and the data incorporated into a Kaplan-Meyer curve. Data were analyzed with the log-rank (Mantel-Cox) test.
DETECTION OF THE LOCATION OF EVs IN CCA MASS OF LIVER
Isolated EVs from LX2-pCDH1-EF1-mCherry-TSG101-IRES-GFP cells were injected into tail veins of CCA rats. After 24 hours, rats were sacrificed and tissue specimens of the tumor mass were frozen in OCT compound. Tissue sections were stained with primary antibodies against mCherry (catalog no.: 632496; Clontech, Mountain View, CA) and alpha-SMA (catalog no.: A2547; Sigma-Aldrich, St. Louis, MO) to detect the injected EVs and measure the degree of fibrotic change in the tumor mass. Furthermore, BDEneu cells infected with pMSCV-loxpdsRed-loxp-eGFP-Puro-WPRE lentiviral construct were injected into rat livers as described above to generate the CCA model, and after 20 days, EVs transfected with Cre plasmid were administered to the rats by tail veil injections. Four to 6 days later, rats were sacrificed and tumor sections obtained as described above. Cells that switched color from dsRed to enhanced GFP (eGFP) indicate BDEneu tumor cells that have taken up EVs loaded with Cre-recombinase plasmid.
PROLIFERATION AND APOPTOSIS MEASUREMENT IN VIVO
Tumor mass specimens were embedded in paraffin, sections were stained with primary antibody Ki67 (catalog no.: 550609; BD, San Jose, CA), caspase 3 (catalog no.: 9661S; Cell Signaling Technology, Dancers, MA), alpha-SMA, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in situ cell death fluorescein (Sigma-Aldrich) to determine levels of proliferation, apoptosis, as well as fibrotic infiltrate. ImageJ software (National Institutes of Health) was used to identify florescence intensity.
Results
CCA CELLS CAUSE DOWN-REGULATION OF miR-195 IN COCULTURED STROMAL CELLS
The stromal components of CCA include fibrotic cells that are likely derived from HSCs and/or portal fibroblasts. (23, 24, (27) (28) (29) The human stellate cell line, LX2, has been extensively utilized for in vitro modelling of stromal cells in CCA. (4, 23, 24, 30, 31) We therefore began our search for selectively down-regulated miRs in the human HSC line, LX2, following their coculture with the HuCCT-1 CCA cell line. (18) HuCCT1 was derived from a patient with a moderately differentiated adenocarcinoma of the intrahepatic biliary tree. (19) We cocultured GFP-expressing HuCCT-1 cells with unlabeled LX2 cells for 14 days, purified the cocultured LX2 cells, extracted their RNA, and compared the abundance of miRs to that of control LX2 cells. Of the 380 miRs that we examined, three were significantly down-regulated in LX2 cells cocultured with CCA cells (Supporting Table S1 ). One of these three was miR-195.
OVEREXPRESSION OF miR-195 IN STROMAL CELLS INHIBITS GROWTH AND INVASIVENESS OF NEIGHBORING CANCER CELLS
It is well established that fibrotic stromal cells can enhance the growth, migration, and invasiveness of cocultured cancer cells, (4, 28) and this has been reported previously for LX2 cells cocultured with CCA cells. (23, 24, 27) Using this in vitro cell-culture model, we tested whether overexpression of miR-195 in LX2 cells would perturb their ability to support the growth and invasiveness of CCA cells. Specifically, we generated LX2 cells that overexpressed either miR-195 (LX2-miR-195 mimic) or a control miR (LX2-NSM) and then examined their effects on the growth of cocultured CCA cells. In each instance, we observed significantly less growth and invasiveness of CCA cells that were cocultured with LX2-miR-195 cells as compared to CCA cells that were cocultured with LX2-NSM cells ( Fig. 1A-C) .
DIFFUSIBLE FACTORS FROM LX2-miR-195 CELLS INHIBIT CCA CELL GROWTH
To determine whether diffusible factors contributed to this antineoplastic property of LX2-miR-195 cells, we utilized conditioned media from LX2 cells to study the effects on CCA cells. Despite the absence of direct contact between cell types, diffusible factors released by LX2-miR-195 cells still caused a significant inhibition in growth, invasiveness, and migration of CCA cells ( Fig. 2A,B ). To test whether EVs alone can induce a phenotypic change in cancer cells, we isolated EVs from LX2 cells and loaded them with miR-195 and nonspecific mimic (NSM), respectively. Next, CCA cells were treated with EVs, and we noted that cells treated with EV-miR-195 invaded less versus EV-NSM (Supporting Fig. S1A ). To investigate whether the observed up-regulation of miR-195 in recipient cancer cells is attributed to direct transduction by EVs or through transcriptional activation, we used as a model system a cancer cell line, DLD1-Dicer-KO, that cannot produce miR species nor can it up-regulate transcriptionally miR synthesis. First, we verified that DLD1-Dicer-KO cells do not express miR-195 (Supporting Fig S1B) . Next, we showed that treatment with EVs-miR-195 versus EVs-NSM induces a vigorous up-regulation of miR-195 in recipient DLD1-Dicer-KO cells (Supporting Fig. S1C ). These data argue that the miR-195 up-regulation in recipient cells is the result of the direct transduction of miR-195 by EVs.
We opined that if miR-195 is, at least in part, responsible for the change in phenotype, then its levels should be elevated in CCA cells following culturing with conditioned media from LX2-miR-195. Indeed, a significant increase in the abundance of CCAassociated miR-195 was noted (Fig. 2C) .
Next, we wanted to assess whether overexpression of miR-195 in LX2 cells caused any changes in EV biogenesis or EV content. To this end, we have contrasted EVs from LX2 cells treated with the control NSM with EVs from LX2 cells treated with miR-195 by nanoparticle tracking analysis (NTA), as described. (26) There was no difference in the numbers of EVs produced by LX2 cells, nor was there any difference in regard to the size of EVs (mode, in the figure; Fig. 3A ). Next, we evaluated whether there were any changes in EV budding induced by overexpression of miR-195. To this end, we performed immunoblottings for budding proteins CD9 and CD63, and we found no difference (Fig. 3B) . Last, we contrasted miR content of EVs from LX2 cells treated with NSM versus miR-195 with qRT-PCR arrays. With the exception of miR-195, expectedly found to be overexpressed 1,580-fold in EVs from LX2 cells transfected with miR-195 versus NSM, the other miR species appeared to be expressed at similar levels, further arguing that transfecting LX2 cells with miR-195 does not change the composition of EVs (Fig 3C) .
Portal fibroblasts are another cell type that is likely to contribute stromal cells to CCA tumors, and we therefore performed similar experiments in the portal fibroblast cell line, RGF. (32) Overexpression of miR-195 in portal fibroblasts resulted in reduced growth of CCA cells as well as reduced invasion of cocultured CCA cells, relative to control experiments (Supporting Fig. S2 ).
miR-195-LOADED EVs INHIBIT CHOLANGIOCARCINOMA GROWTH IN VIVO AND PROLONG SURVIVAL
In addition to the many possible secreted proteins, lipids, and other small molecules that might contribute to these cancer-inhibitory effects, recent studies have established that EVs (also known as exosomes and microvesicles) can influence the behavior of neighboring cells. (14, 33, 34) To test whether EVs might mediate at least part of the antineoplastic effects of LX2-miR-195 cells, we collected EVs from LX2-miR-195 cells and from control cells LX2-NSM cells by ultrafiltration and differential centrifugation of tissue culture supernatants. These vesicles had the expected properties of EVs as determined by NTA, immunoblotting for exosomal marker proteins, and electron microscopy (Supporting Fig. S3A-D) . Furthermore, we observed that EVs collected from LX2-miR-195 cells contained elevated levels of miR-195 (Supporting Fig. S3E ), raising the possibility that miR-195-loaded EVs might be able to inhibit the neoplastic properties of CCA cells. To test this hypothesis, we used a CCA model involving outbred Fischer 344 rats that had been injected with the rat CCA line, BDEneu (intrahepatic injection of Fischer rats with BDEneu cells leads to the formation of CCA in all animals, rapid growth of the tumors, and death in 30 days). (22, 27) Specifically, we purified EVs from LX2 cells, transfected these EVs with miR-195 or a nonspecific mimic (miR-NSM), and injected them every second day into the tail vein of rats that had been inoculated with BDEneu cells 5 days previously. This EV injection regimen was continued for 25 days. Animals were then sacrificed, their livers excised, and their tumors examined. Treatment with miR-195-loaded EVs inhibited CCA growth, shown here by a significant reduction in tumor size and mass (Fig. 4A-D) . Inhibition of cancer growth is one of the most frequently cited outcomes in clinical oncology. However, one of the most important outcomes of any anticancer therapy is increased survival. We therefore tested whether injection of miR-195-loaded, LX-2-derived EVs increased the survival of cancer-bearing animals. We found that treatment with miR-195-loaded EVs significantly prolonged mean animal survival by 28.7% (from mean survival of 25.7 days to 33.1 days; Fig. 4E ).
miR-195-LOADED EVs SUPPRESS CANCER CELL PROLIFERATION MARKERS AND miR-195 TARGETS
To better understand how miR-195-loaded, LX2-derived EVs inhibited CCA growth in vivo, we excised tumors from treated and control animals and examined them for expression of cell proliferation, desmoplasia, and apoptosis markers, as well as known miR-195 target mRNAs. Consistent with the reduced growth of tumors in treated animals, we observed that Ki67 expression was significantly lower in cancers from animals injected with miR-195-loaded EVs (relative to its levels in tumors from animals injected with the same amount of miR-NSM-loaded EVs; Fig. 5A,B) . As for the desmoplastic reaction in these tumors, staining for alpha smooth muscle actin (a-SMA) was reduced following treatment with miR-195-loaded EVs (Fig. 5C,D) . In contrast, we failed to detect a significant difference in apoptosis TUNEL assay and caspase3 expression between tumors from treated and mock-treated animals (Supporting Fig. S4) , although there was a trend toward increased apoptosis in tumors from treated rats (Supporting Fig. S4 ). These findings indicate that miR-195-loaded EVs cause reduced tumor size, at least in part, by inhibiting CCA cell growth and degree of desmoplasia.
The only difference between the experimental and control EVs was the sequence of the transfected miR (miR-195 vs. miR-NSM). Therefore, it is reasonable to presume that miR-195-loaded EVs were exerting their effects on CCA cells by delivering miR-195 into tumor cells and suppressing expression of miR-195 targets. To test this presumption, we extracted RNAs from tumors of treated and control-treated animals and first measured the relative levels of miR-195 itself, as well as the levels of known miR-195 targets. As expected, abundance of miR-195 was significantly and selectively elevated in tumors from animals injected with miR-195-loaded EVs (Fig. 6A) . Furthermore, we observed that tumors from these animals displayed a ) were plated in triplicate for NSM and miR-195 treatment, respectively. Three days after transfection with NSM and miR-195, respectively, media were collected for EV counting and size measurements. Cells were also counted, and the number of EVs was calculated per milliliter of media per cell. We found that LX2 cells treated with miR-195 made 47.8*eÙ9 6 0.98*eÙ9 particles/mL/cell and LX2 cells treated with NSM made 53.2*eÙ9 6 0.47*eÙ9 particles/mL/cell. There was no statistical difference between the numbers of EVs produced over 3 days by any of the cell lines. In addition, the mode of EVs was the same in NSM-versus miR-195-treated cells (93.1 6 3.9 nm vs. 94.1 6 6.6 nm). (B) EV budding proteins CD9 and CD63 were analyzed by immunoblotting, performed in six replicates per condition. There was no statistically significant difference between budding of EVs from NSM-versus miR-195-treated cells, as measured by CD9 and CD63 blotting. (C) EVs collected 3 days after LX2 transfection with NSM or miR-195, respectively, were subjected to RNA extraction followed by qRT-PCR arrays. As shown, five miRs were expressed in EVs from NSM-transfected LX2 cells. These miRs were expressed at similar levels in EVs from miR-195-transfected LX2 cells. In contrast, miR-195 was expressed 1,580-fold more in EVs from miR-195-versus NSM-transfected LX2 cells. significant reduction in each of six known miR-195 targets (Fig. 6B,C) . Inhibition of these known miR-195 targets was also observed in vitro for CCA cells transfected with miR-195 (Fig. 6D,E) , indicating that the reduction in these miR-195 targets in vivo was likely the effect of miR-195 expression rather than an indirect effect of reduced tumor size.
In the context of these observations, we asked whether levels of miR-195 are down-regulated in CCA tumors relative to the normal liver parenchyma in the same patients. RNA was extracted from 20 human CCA specimens and matched normal specimens and tested for miR-195 abundance by qRT-PCR. miR-195 was selectively down-regulated in tumor tissue in 16 of 20 paired samples (Fig. 7A) . miR-195 levels were also reduced in several CCA cell lines (relative to a normal cholangiocyte cell line; Fig. 7B ) and in the more-malignant BDEneu cells versus the related, but less-malignant, BDEsp cells (Fig. 7C) . We also observed that culturing CCA cells with LX2 cells results in a further reduction of miR-195 in CCA cells (Fig 7D,E) , as well as its reduction in LX2 cells ( Fig. 7F ; Supporting Table S1 ). Taken together, these results are consistent with the hypothesis that miR-195 is an inhibitor of CCA growth. In support of this idea, we observed that overexpression of miR-195 inhibited the growth and invasiveness of four CCA cell lines (Supporting Fig. S5 ).
LX2-DERIVED EVs SELECTIVELY TARGET CCA TUMOR CELLS IN VIVO
To determine whether LX2-derived vesicles show any tropism for CCA cells in vivo, we first generated LX2 cells that express a tagged exosomal marker protein, mCherry-TSG101.These cells were then verified to produce fluorescent EVs that can be detected by immunohistochemistry. These EVs were collected, purified, and injected into animals carrying BDEneuinduced tumors, followed by histological examination of cancer slides. Labeling for the tagged exosomal marker showed strong staining in the tumors themselves, with no evidence of EV accumulation in the unaffected liver parenchyma (Fig. 8A,B) . We performed similar experiments using a BDEneu cell line carrying a Cre reporter gene that expresses dsRed in the absence of Cre, but expresses EGFP following the expression of Cre. These Cre reporter BDEneu cells were injected into livers of Fischer rats, followed by tail vein injection of EVs loaded with Cre. Tumors from animals injected with control LX2-derived EVs contained many dsRed-expressing cells, but were devoid of any eGFP-expressing BDEneu cells. However, tumors from paired animals injected with Cre-loaded EVs contained many eGFP-expressing cells (Fig. 8C) , demonstrating that LX2-derived EVs were delivered to the cancer cells, and also that LX2-derived EVs can be used to deliver functional nucleic acids to CCA cells in vivo.
Next, we investigated whether the origin of EVs (fibroblast vs. other cell types) confers any tropism to CCA cells. To this end, we utilized three cell types-LX2, HEK293T, and HeLa-as EV donors. We found that recipient CCA cells SG231 appear to increase miR-195 levels significantly more in response to treatment with EVs-miR-195 from donor LX2 cells versus donor HEK293T or donor HeLa cells (Supporting Fig. S6 ). Similar results were obtained for recipient CCA cells (HuCCT1), as well as for recipient CCA cells (BDEneu). In contrast, recipient CCA cells (TFK1 cells) appear to be less effectively transduced by EVs from donor LX2 cells or donor HECK293T versus EVs from donor HeLa cells. We Ki67 staining was performed on slides cut from cancer blocks (n 5 3 rats, four slides per rat). (C,D) a-SMA staining was performed on slides cut from cancer blocks (n 5 3 rats, four slides per rat). ImageJ software (National Institutes of Health, Bethesda, MD) was used to quantify fluorescence. Significance was analyzed using the two-tailed Student t test: *P < 0.05. Abbreviation: DAPI, 4 0 ,6-diamidino-2-phenylindole.
conclude that there appears to be a tropism of LX2-derived EVs to some CCA cells, but not to others. We also noted that the relative tropism of LX2 derived EVs versus EVs from other donor cells varies as a function of recipient CCA cells. For example, it appears that whereas CCA cells (SG231 and TFK1) are transduced more effectively by EVs from HeLa versus HEK293T cells, HuCCT1 and BDEneu cells are transduced more effectively by EVs from donor HEK293T versus HeLa cells. Further studies are necessary to precisely identify the factors that influence the relative tropism of EVs for CCA cells as a function of the EV donor cell type and characteristics of recipient CCA cells.
Discussion
CCA is an extremely aggressive cancer of the bile duct epithelium. (35) Currently, the only curative treatment is surgery. (37) Unfortunately, very few patients are surgical candidates because of late diagnoses. (37) In the face of such a lethal disease, it is urgent that we learn more about the mechanisms that initiate and promote the growth of CCA tumors, but also that we apply our findings about CCA to the development of novel therapeutic paradigms for other cancers with a strong fibrotic reaction (pancreatic cancer, subtypes of breast cancers, and others). In this report we improved our understanding of CCA biology by searching for, and identifying, an inhibitor of cancer support pathway(s) in stromal cells. This inhibitor of stromal support pathways, miR-195, was repressed in both CCA cells and in their neighboring stromal cells, and its overexpression in stromal cells led to reduced growth and invasiveness of neighboring CCA cells. We also observed that stroma-derived EVs displayed selective targeting to CCA in vivo, and, most important, that systemic injections of miR-195-loaded, stroma-derived EVs suppressed tumor growth and prolonged survival in a rat model of CCA. Our findings are consistent with other reports implicating miR-195 as an inhibitor of cancer growth, (38) (39) (40) while also being the first report of miR-195 down-regulation in CCA. Although an exhaustive identification of mechanisms of action downstream of miR-195 in tumors of treated animals is beyond the scope of this study, we noted that miR-195 does inhibit several known mRNA targets, including genes that have been implicated as miR-195 targets in other cancers. For example, VEGF, CDC42, CDK1, CDK4, CDK6, and CDC25 were previously reported to be downregulated by miR-195 in hepatocellular carcinoma. (38, 39, 41) Given that almost all investigators studying the antineoplastic effects of miR-195 expression focused on distinct target genes, it is likely that miR-195 mediates its effects by simultaneously suppressing multiple proneoplastic factors in each of these cancers, including CCA. In this context, future studies aimed at elucidating the molecular mechanisms by which miR-195-loaded EVs inhibit CCA growth is likely to require a systematic, unbiased survey of the transcriptome in tumors from treated and untreated animals.
Whereas the down-regulation of miR-195 in CCA cells might have been expected from other studies, its down-regulation in stromal cells exposed to CCA is unexpected and intriguing. Given that we now know that CCA-exposed stromal cells release EVs that are taken up by CCA cells, and target miR-195 into these vesicles, it is formally possible that miR-195 inhibition in stromal cells is necessary to maintain its repression in cancer cells. These observations also indicate that stroma-derived EVs are uniquely suited to deliver materials to CCA cells, and that this property can be exploited for delivering antineoplastic therapies to CCA cells. This conclusion is supported by the targeting of stroma-derived EVs to CCA tumors and cells in vivo. This tropism likely has a molecular basis, and a major focus of future studies will be to identify and characterize the factors that mediate this targeting, both on the stroma-derived EVs and on the surface of CCA cells.
The findings presented herein, along with other recent studies, bring EVs into the spotlight. Intense research continues to add to our understanding of the (16) Subsequently, EVs were found to participate in the intercellular communication networks in other organs and systems. (15, 17) Their potential clinical utility as delivery vehicles has recently been explored in a xenograft mouse model of breast cancer where HEK293-derived EVs loaded with let7a-mimic were administered by tail vein injections and showed markedly suppressed tumor growth. (42) Recent data suggest roles of EVs in stromal myofibroblasts; however, their role as intercellular communication conduits in epithelial cancer cells and neighboring CAFs has not yet been fully explored. (2, 3) Cancers with a strong desmoplastic reaction-such as CCAs and pancreatic cancers-are notoriously difficult to treat with conventional chemotherapy. The current study suggests that the development and implementation of additional strategies-such as injection of miRloaded EVs-may have positive outcomes in these difficult-to-treat cancers. Additional studies are now needed to explore the safety of EV-mediated therapies, the efficacy of stroma-derived EVs loaded with multiple antineoplastic miRs, and whether these vesicles can also deliver therapeutic drugs and proteins to CCA.
Our studies also shed light on the benefits of studying cancer-stroma interactions in a simple in vitro cellculture system. Although it would obviously be best to elucidate these interactions in vivo and in the context of a tumor, simple cell-culture systems such as the one we used allow greater experimental control. Importantly, we maintained our stromal cells in the presence of CCA cells or their conditioned medium, in accord with the hypothesis that the CAF state is dependent upon the presence of cancer cells and might be otherwise unstable.
(5) Nevertheless, we chose cell lines that represent the types of fibrotic stromal cells that are present at the sites of CCA, both a stellate cell line (LX2) and portal fibroblast line (RGF). (23, 24) The rationale for utilizing liver-derived stellate and portal fibroblast cell lines rests with observations that these cell types are the main sources of liver fibrogenesis, (18, 32) and that stellate cells participate in the desmoplastic liver reaction induced by cancers. (43) In addition, LX2 cells have been shown to recapitulate CAF behaviors, such as up-regulating chemokine (C-X-C motif) ligand 5 CXCL5 in CCA cells, (44) increasing proliferation and invasion of CCA cells, (23, 24) inhibiting apoptosis in CCA cells, activating the mitogen-activated protein kinase MAPK and protein kinase B AKT pathways in CCA cells, and enhancing CCA tumor growth in vivo. It remains to be determined whether the origin of fibroblast-like cells is paramount to the in vitro modeling of CCA interactions with stellate or other fibroblast-like cells.
